Bring early confidence to your asset selection with clinically relevant, patient-derived ex vivo models. Our Discovery Package is designed for Pharma and Biotech teams who need fast, actionable data to prioritize compounds, optimize combinations, and establish a translational rationale before significant investment.
Why Discovery with CliniSciences
Traditional 2D cell lines often fail to predict clinical response, while PDX models are costly and slow. Our platform bridges this gap by testing therapies directly on primary tumor cells, preserving tumor heterogeneity and delivering functional efficacy readouts that are closer to real clinical behavior.
Key outcomes
- Faster go/no-go decisions
- Reduced late-stage attrition risk
- Stronger translational story for IND/partnering
- Earlier identification of responsive tumor profiles
What’s included
1) Study design & feasibility
We work with you to define:
- Indication and cohort strategy (e.g., colorectal, breast, ovarian, lung, glioblastoma; others on request)
- Therapy type: small molecules, antibodies, ADCs, bispecifics, peptides/proteins, radiotherapy combinations, immunomodulators
- Dosing strategy and endpoints (single-agent, combination, synergy)
Deliverables:
- Written study plan, timeline, acceptance criteria
- Recommendations for cohort size and statistical approach (exploratory)
2) Patient-derived ex vivo tumor testing
Functional testing performed on primary tumor cultures under standardized conditions:
- Monotherapy activity profiling
- Combination screening (standard of care + your asset, or asset + asset)
- Dose–response and ranking across patient samples
- Optional kinetic evaluation (early vs late effects)
3) Mechanism-supporting readouts (optional modules)
Choose the level of biological depth needed for your program:
Cell fate & viability
- Luminescence viability
- Calcein AM / Ethidium homodimer live/dead
- MTT
- Ki-67 proliferation
- BrdU incorporation
- TUNEL / apoptosis-associated readouts
- Soluble nucleosome ELISA
Protein & phenotypic profiling
- Western blot / SDS-PAGE
- Flow cytometry
- Immunocytochemistry / immunohistochemistry
- Target engagement and pathway modulation (custom panels)
Molecular biology
- RNA extraction, RT, PCR/qPCR
- Fragment analysis
- Cloning/sequencing (as needed for research use)
Typical use cases
- Lead selection: prioritize the best-in-class candidate using patient-relevant functional efficacy
- Combination strategy: identify additive/synergistic combinations and rank them by impact
- Indication expansion: screen activity across multiple tumor types to spot new opportunities
- Biomarker hypothesis building: link functional responders vs non-responders to molecular/protein signals
- Rescue programs: re-evaluate compounds with weak cell-line data using patient-derived model
What you receive (deliverables)
- Executive summary with clear conclusions and recommendations
- Ranked efficacy profiles (single-agent and/or combinations)
- Dose–response curves and potency metrics (when applicable)
- Patient-sample level response stratification (responder patterns)
- Optional mechanistic package (pathway/phenotype/molecular readouts)
- Clean dataset + report ready for internal review, partnering, or investor updates
Differentiators
- Patient-derived primary tumor cultures (clinically closer than cell lines)
- Standardized functional assay conditions enabling comparability across samples
- Expertise rooted in functional precision oncology and ex vivo tumor modeling
- Designed to support both R&D decisions and translational narratives
